FibroBiologics Interim CFO Robert Hoffman resigns effective May 14, 2025

FibroBiologics, Inc.

Robert E. Hoffman resigned as Interim CFO effective May 14 to pursue another opportunity.
Hoffman will remain on the Board of Directors as a Class I director.
Company will initiate a search for a new CFO successor.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Robert E. Hoffman

Interim Chief Financial Officer

FBLG · FibroBiologics, Inc.

Effective: 2025-05-14
Filed: May 5, 2025, 7:59 PM ET

On May 2, 2025, Mr. Robert E. Hoffman informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Interim Chief Financial Officer, effective as of the close of business on May 14, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Hoffman resigned as Interim Chief Financial Officer at FibroBiologics, Inc..

Action: resigned
Role: Interim Chief Financial Officer

Exact text from the filing

On May 2, 2025, Mr. Robert E. Hoffman informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Interim Chief Financial Officer, effective as of the close of business on May 14, 2025.

View on SEC.gov

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-008680

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.